Analysts See Daiichi Weathering Ranbaxy Merger Fallout
This article was originally published in PharmAsia News
Daiichi Sankyo's beginnings as the parent of Ranbaxy Laboratories of India is costing the Japanese firm in the short run, but the deal still is expected to be beneficial in the long run, according to analysts. Since acquiring Ranbaxy, Daiichi has seen its shares under pressure because of problems with two of the Indian drug maker's factories that led to a temporary U.S. ban on its products. Analysts expect Daiichi to weather the fallout and become more stable with Ranbaxy as a subsidiary. (Click here for more - a subscription may be required
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.